NOVELIX PHARMACEUTICALS LIMITE Stock Price Today (NSE: NOVELIX)
NOVELIX PHARMACEUTICALS LIMITE
Fundamental Score
NOVELIX PHARMACEUTICALS LIMITE Share Price Live NSE/BSE & Institutional Fundamental Analysis
NOVELIX PHARMACEUTICALS LIMITE share price today is ₹61.39, up +0.00% on NSE/BSE as of 17 February 2026. NOVELIX PHARMACEUTICALS LIMITE (NOVELIX) is a Small-cap company in the Healthcare Research, Analytics & Technology sector with a market capitalisation of ₹101.70 (Cr). The 52-week high for NOVELIX share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 104.85x, NOVELIX is currently trading above its industry average P/E of 45.95x. The company has a Return on Equity (ROE) of 0.64% and a debt-to-equity ratio of 0.00.
NOVELIX PHARMACEUTICALS LIMITE Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
NOVELIX PHARMACEUTICALS LIMITE Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
NOVELIX PHARMACEUTICALS LIMITE Share Price: A Conservative Investor's Perspective
The healthcare research, analytics, and technology sector is currently experiencing a surge in data-driven approaches to drug discovery and personalized medicine. However, identifying companies with strong fundamentals remains crucial for value investors prioritizing capital preservation. This analysis examines the NOVELIX PHARMACEUTICALS LIMITE share price, currently at ₹63.75, through a conservative lens, focusing on key financial metrics and comparative performance.
A significant concern for a value investor is NOVELIX PHARMACEUTICALS LIMITE's high Price-to-Earnings (PE) ratio of 104.85. This suggests the market has high expectations for future earnings growth, which may be vulnerable to economic downturns. Comparatively, assessing management quality across the sector is paramount. For instance, when viewing peers,
Suven Life Sciences Ltd, has historically displayed a different operational tempo when looking at efficient use of resources. It is crucial to evaluate management's strategic decisions and capital allocation skills relative to peers. The management must focus on sustainable use of resources.The Return on Capital Employed (ROCE) of 0.96% is particularly alarming. ROCE measures how efficiently a company generates profit from its capital. A low ROCE such as this might indicate challenges in maintaining a competitive advantage, or "moat." With returns this slim, competitors might be able to erode their market share. Consider, for example, that this return is a percentage of total capital employed, meaning even small inefficiencies significantly impact profitability. This low ROCE casts doubt on NOVELIX PHARMACEUTICALS LIMITE's ability to generate sustainable returns and reinvest in its business for future growth.
Given the current financial data, a prudent, safety-focused investor might adopt a wait-and-see approach. Further investigation into the underlying drivers of the low ROCE and high PE ratio would be warranted. This analysis forms part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra and aims to provide an objective assessment based on publicly available information.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
NOVELIX PHARMACEUTICALS LIMITE Fundamental Analysis & Valuation Benchmarking
Educational evaluation of NOVELIX across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Robust Profit Growth (307.69%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (818.18%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (82.92% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (54.82%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (0.64%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (0.96%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-12.77%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Premium Valuation Risk (P/E: 104.85x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (-6.26% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-2.33% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Negative Free Cash Flow (₹-17.48 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
NOVELIX PHARMACEUTICALS LIMITE Financial Statements
Comprehensive financial data for NOVELIX PHARMACEUTICALS LIMITE including income statement, balance sheet and cash flow
About NOVELIX (NOVELIX PHARMACEUTICALS LIMITE)
NOVELIX PHARMACEUTICALS LIMITE (NOVELIX) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Healthcare Research, Analytics & Technology sector with a current market capitalisation of ₹101.70 (Cr). NOVELIX PHARMACEUTICALS LIMITE has delivered a Return on Equity (ROE) of 0.64% and a ROCE of 0.96%. The debt-to-equity ratio stands at 0.00, reflecting the company's capital structure. Investors tracking NOVELIX share price can monitor key metrics including P/E ratio, promoter holding of 54.82%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
Latest News
NOVELIX Share Price: Frequently Asked Questions
What is the current share price of NOVELIX PHARMACEUTICALS LIMITE (NOVELIX)?
As of 17 Feb 2026, 10:17 am IST, NOVELIX PHARMACEUTICALS LIMITE share price is ₹61.39. The NOVELIX stock has a market capitalisation of ₹101.70 (Cr) on NSE/BSE.
Is NOVELIX share price Overvalued or Undervalued?
NOVELIX share price is currently trading at a P/E ratio of 104.85x, compared to the industry average of 45.95x. Based on this relative valuation, the NOVELIX PHARMACEUTICALS LIMITE stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of NOVELIX share price?
The 52-week high of NOVELIX share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the NOVELIX PHARMACEUTICALS LIMITE share price?
Key factors influencing NOVELIX share price include quarterly earnings growth (Sales Growth: 818.18%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is NOVELIX PHARMACEUTICALS LIMITE a good stock for long-term investment?
NOVELIX PHARMACEUTICALS LIMITE shows a 5-year Profit Growth of -2.33% and an ROE of 0.64%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in NOVELIX shares.
How does NOVELIX PHARMACEUTICALS LIMITE compare with its industry peers?
NOVELIX PHARMACEUTICALS LIMITE competes with major peers in the Healthcare Research, Analytics & Technology. Investors should compare NOVELIX share price P/E of 104.85x and ROE of 0.64% against the industry averages to determine competitive standing.
What is the P/E ratio of NOVELIX and what does it mean?
NOVELIX share price has a P/E ratio of 104.85x compared to the industry average of 45.95x. Investors pay ₹105 for every ₹1 of annual earnings.
How is NOVELIX performing according to Bull Run's analysis?
NOVELIX has a Bull Run fundamental score of 40.6/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does NOVELIX belong to?
NOVELIX operates in the Healthcare Research, Analytics & Technology industry. This classification helps understand the competitive landscape and sector-specific trends affecting NOVELIX PHARMACEUTICALS LIMITE share price.
What is Return on Equity (ROE) and why is it important for NOVELIX?
NOVELIX has an ROE of 0.64%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently NOVELIX PHARMACEUTICALS LIMITE generates profits from shareholders capital.
How is NOVELIX debt-to-equity ratio and what does it indicate?
NOVELIX has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is NOVELIX dividend yield and is it a good dividend stock?
NOVELIX offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in NOVELIX PHARMACEUTICALS LIMITE shares.
How has NOVELIX share price grown over the past 5 years?
NOVELIX has achieved 5-year growth rates of: Sales Growth 82.92%, Profit Growth -2.33%, and EPS Growth -6.26%.
What is the promoter holding in NOVELIX and why does it matter?
Promoters hold 54.82% of NOVELIX shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in NOVELIX PHARMACEUTICALS LIMITE.
What is NOVELIX market capitalisation category?
NOVELIX has a market capitalisation of ₹102 crores, placing it in the Small-cap category.
How volatile is NOVELIX stock?
NOVELIX has a beta of N/A. A beta > 1 suggests the NOVELIX PHARMACEUTICALS LIMITE stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is NOVELIX operating profit margin trend?
NOVELIX has a 5-year average Operating Profit Margin (OPM) of -12.77%, indicating the company's operational efficiency.
How is NOVELIX quarterly performance?
Recent quarterly performance shows NOVELIX PHARMACEUTICALS LIMITE YoY Sales Growth of 818.18% and YoY Profit Growth of 307.69%.
What is the institutional holding pattern in NOVELIX?
NOVELIX has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the NOVELIX PHARMACEUTICALS LIMITE stock.